139 related articles for article (PubMed ID: 27346574)
1. CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas.
Pascual-García M; Bértolo C; Nieto JC; Serrat N; Espinosa Í; D'Angelo E; Muñoz R; Rovira R; Vidal S; Prat J
Hum Pathol; 2016 Oct; 56():180-8. PubMed ID: 27346574
[TBL] [Abstract][Full Text] [Related]
2. Immunoexpression of B7-H3 in endometrial cancer: relation to tumor T-cell infiltration and prognosis.
Brunner A; Hinterholzer S; Riss P; Heinze G; Brustmann H
Gynecol Oncol; 2012 Jan; 124(1):105-11. PubMed ID: 21982044
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma.
Kondratiev S; Sabo E; Yakirevich E; Lavie O; Resnick MB
Clin Cancer Res; 2004 Jul; 10(13):4450-6. PubMed ID: 15240536
[TBL] [Abstract][Full Text] [Related]
4. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Crumley S; Kurnit K; Hudgens C; Fellman B; Tetzlaff MT; Broaddus R
Mod Pathol; 2019 Mar; 32(3):396-404. PubMed ID: 30291344
[TBL] [Abstract][Full Text] [Related]
5. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.
Miyatake T; Tringler B; Liu W; Liu SH; Papkoff J; Enomoto T; Torkko KC; Dehn DL; Swisher A; Shroyer KR
Gynecol Oncol; 2007 Jul; 106(1):119-27. PubMed ID: 17509674
[TBL] [Abstract][Full Text] [Related]
6. The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Vagios S; Yiannou P; Giannikaki E; Doulgeraki T; Papadimitriou C; Rodolakis A; Nonni A; Vlachos A; Pavlakis K
Int J Clin Oncol; 2019 Nov; 24(11):1419-1428. PubMed ID: 31197557
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.
Ikeda Y; Kiyotani K; Yew PY; Sato S; Imai Y; Yamaguchi R; Miyano S; Fujiwara K; Hasegawa K; Nakamura Y
Oncol Rep; 2017 May; 37(5):2603-2610. PubMed ID: 28358435
[TBL] [Abstract][Full Text] [Related]
8. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
9. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.
de Jong RA; Leffers N; Boezen HM; ten Hoor KA; van der Zee AG; Hollema H; Nijman HW
Gynecol Oncol; 2009 Jul; 114(1):105-10. PubMed ID: 19411095
[TBL] [Abstract][Full Text] [Related]
10. Intraepithelial lymphocytes are indicators of better prognosis in surgically resected endometrioid-type endometrial carcinomas at early and advanced stages.
Kono-Sato T; Miyai K; Yamagishi Y; Miyamoto M; Takano M; Matsukuma S; Sato K; Tsuda H
BMC Cancer; 2022 Apr; 22(1):361. PubMed ID: 35366828
[TBL] [Abstract][Full Text] [Related]
11. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
[TBL] [Abstract][Full Text] [Related]
12. Zone Formation of Lymphocyte Infiltration at Invasive Front as a Biomarker of Prognosis in Endometrial Carcinomas.
Miyamoto M; Takano M; Tsuda H; Matuura H; Aoyama T; Soyama H; Kato K; Iwahashi H; Ishibashi H; Yoshikawa T; Suzuki A; Hirata J; Furuya K
Oncology; 2019; 96(2):93-100. PubMed ID: 30282081
[TBL] [Abstract][Full Text] [Related]
13. Endometrial Cancer Suppresses CD8+ T Cell-Mediated Cytotoxicity in Postmenopausal Women.
Patel MV; Shen Z; Rodriguez-Garcia M; Usherwood EJ; Tafe LJ; Wira CR
Front Immunol; 2021; 12():657326. PubMed ID: 33968059
[TBL] [Abstract][Full Text] [Related]
14. The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations.
Willvonseder B; Stögbauer F; Steiger K; Jesinghaus M; Kuhn PH; Brambs C; Engel J; Bronger H; Schmidt GP; Haller B; Weichert W; Keller G; Noske A; Pfarr N; Boxberg M
Cancer Immunol Immunother; 2021 Jun; 70(6):1679-1689. PubMed ID: 33340331
[TBL] [Abstract][Full Text] [Related]
15. The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment.
Versluis MAC; Marchal S; Plat A; de Bock GH; van Hall T; de Bruyn M; Hollema H; Nijman HW
Eur J Cancer; 2017 Nov; 86():285-295. PubMed ID: 29059634
[TBL] [Abstract][Full Text] [Related]
16. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of intratumoral lymphocytes and FOXP3 expression in tumor cells of endometrial cancer.
Iurchenko NP; Glushchenko NM; Buchynska LG
Exp Oncol; 2014 Dec; 36(4):262-6. PubMed ID: 25537221
[TBL] [Abstract][Full Text] [Related]
20. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody.
Bignotti E; Ravaggi A; Romani C; Falchetti M; Lonardi S; Facchetti F; Pecorelli S; Varughese J; Cocco E; Bellone S; Schwartz PE; Rutherford TJ; Santin AD
Int J Gynecol Cancer; 2011 Dec; 21(9):1613-21. PubMed ID: 21892093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
